N-Acetyl Semax

Background

N‑Acetyl Semax is a synthetic, N‑terminally acetylated analogue of Semax, itself a heptapeptide derived from adrenocorticotropic hormone (ACTH) fragment 4–7 extended by the C‑terminal Pro‑Gly‑Pro (PGP) tripeptide (ACTH(4–7)–PGP).[11][15] Semax has the sequence Met‑Glu‑His‑Phe‑Pro‑Gly‑Pro and is classified as an ACTH‑like regulatory peptide.[14][15] The N‑acetylated derivative (often denoted Ac‑Semax or N‑Acetyl‑Semax) preserves the core Semax sequence with an added N‑terminal acetyl group, intended to increase metabolic stability and potentially modify receptor interactions; however, primary literature on N‑Acetyl Semax specifically is limited, and most mechanistic data derive from the parent Semax.[11][14][15]

Semax was developed in Russia in the late 20th century as a neuroprotective and nootropic agent and is clinically used there, particularly in ischemic stroke and certain cognitive disorders.[11][15] N‑terminal acylation is a common medicinal chemistry modification to enhance peptide half‑life and reduce proteolysis, and N‑Acetyl Semax is generally discussed in research and grey literature as a modified Semax with similar pharmacodynamic profile but potentially altered pharmacokinetics. Peer‑reviewed, N‑Acetyl‑Semax–specific pharmacokinetic or clinical outcome data remain sparse as of the available literature.

Mechanism of action

Mechanistic characterization is established for Semax; N‑Acetyl Semax is presumed to act via similar pathways because the pharmacophore (ACTH(4–7)‑PGP) is preserved, but this remains inferential rather than directly demonstrated in vivo.

Key mechanisms described for Semax include:

• Modulation of neurotrophin expression. In a rat model of permanent middle cerebral artery occlusion (pMCAO), Semax increased mRNA levels of neurotrophins (Bdnf, Ngf, Ntf4/5) and their receptors (Ntrk2/TrkB, Ngfr/p75NTR) in ischemic cortex compared with untreated animals, indicating activation of neurotrophic support pathways after cerebral ischemia.[11]
• Regulation of ischemia‑disrupted gene expression. Transcriptomic analysis in rats subjected to transient middle cerebral artery occlusion (tMCAO) showed that ACTH‑like peptides including Semax (ACTH(4–7)PGP) and related ACTH(6–9)PGP peptides modulated hundreds of differentially expressed genes in the ischemic frontal cortex, affecting inflammation, neurotransmission, and neuroplasticity pathways.[15]
• Interaction with metal ion–Aβ systems. In biophysical studies, Semax formed stable complexes with Cu²⁺ and inhibited copper‑induced aggregation of β‑amyloid (Aβ₁–₄₂) and related oligomer formation in membrane‑mimetic systems, suggesting anti‑amyloidogenic properties that may be relevant to neurodegeneration.[13][14]

Receptor‑level binding for Semax has not been fully resolved. It is frequently described as ACTH‑like but does not reproduce classical endocrine effects of ACTH at melanocortin receptors, implying that its primary actions are neuromodulatory rather than endocrine. The PGP motif is also known from other peptides that can influence inflammatory and extracellular matrix pathways, and transcriptomic data support broad modulation of cytokine, cell‑adhesion, and synaptic genes by Semax.[15]

For N‑Acetyl Semax, the acetyl modification at the N‑terminus would be expected to:

• Reduce susceptibility to aminopeptidases and increase plasma or tissue half‑life (by analogy to other N‑acetyl peptides), and
• Slightly alter charge distribution and possibly receptor affinity.

However, direct receptor binding, signaling, or comparative pharmacokinetic data between Semax and N‑Acetyl Semax were not identified in indexed, peer‑reviewed sources, and statements about N‑Acetyl Semax mechanisms must therefore be inferred from Semax itself.[11][13][14][15]

Evidence summary

Preclinical evidence (Semax)

• Cerebral ischemia – neurotrophin transcription (rats). In a pMCAO model, Semax administration upregulated Bdnf, Ngf, Ntf4/5 and their receptor genes in ischemic cortex versus controls, with selective effects in the ischemic hemisphere.[11] Sample sizes were not large (typical n≈6–10 per group, as is common in such models), but the study used quantitative PCR and appropriate controls.
• Stroke‑related transcriptomics (rats). In rats subjected to tMCAO, ACTH‑like peptides including Semax altered expression of hundreds of genes 24 h after ischemia in the ipsilateral frontal cortex, partially compensating ischemia‑induced gene expression changes in pathways related to inflammation, cell death, and synaptic function.[15] This provides systems‑level support for neuroprotective action but is not itself a functional outcome study.
• Amyloid aggregation and toxicity (in vitro). Semax inhibited Cu²⁺‑induced Aβ₁–₄₂ aggregation in micellar and liposomal membrane models, reduced formation of toxic oligomeric species, and mitigated Aβ–Cu²⁺‑related cytotoxicity in cellular viability assays.[13][14] These data support potential disease‑modifying actions in amyloid‑related neurodegeneration but remain preclinical.

Clinical evidence

Semax has been used clinically in Russia and some other Eastern European countries, particularly for ischemic stroke and cognitive disorders; however, many clinical reports are in Russian‑language journals and are not comprehensively indexed in PubMed. The available English‑language literature that directly quantifies outcomes remains limited.[11][15]

• The Semax stroke literature typically describes improved neurological scores and functional recovery versus standard care, often in open‑label or small randomized designs, but specific sample sizes and trial names are not systematically available in major English‑language databases. The experimental stroke work in rodents provides mechanistic support for these clinical uses.[11][15]

For N‑Acetyl Semax specifically, no robust, indexed clinical trials or large observational series were identified. Thus, any claims about its clinical efficacy rest largely on extrapolation from Semax plus non‑indexed or grey literature, and should be considered insufficiently evidenced in peer‑reviewed sources.

Clinical and research uses

Approved and routine uses (Semax)

• In the Russian Federation and some neighboring countries, Semax is used as a neuroprotective agent in acute ischemic stroke, usually as part of hospital‑based therapy, and as a nootropic or cognitive enhancer in certain neuropsychiatric or neurodevelopmental conditions (e.g., attention or learning disorders).[11][15] These uses are based on national regulatory approvals and local clinical trials, although detailed English‑language regulatory dossiers are not readily accessible.

Investigational or exploratory uses

• Neurodegeneration and amyloidopathies. The demonstrated ability of Semax to modulate Aβ aggregation and Cu²⁺ binding has prompted interest in its potential as an anti‑amyloid agent, but this remains at the preclinical stage.[13][14]
• Post‑stroke plasticity and recovery. Transcriptomic and neurotrophin‑expression data suggest possible utility not only in acute neuroprotection but also in promoting post‑ischemic neuroplasticity and recovery.[11][15]

For N‑Acetyl Semax, reported uses are predominantly off‑label or experimental as a “modified Semax” intended to prolong action or enhance stability. Peer‑reviewed documentation of its clinical deployment, indications, or outcomes remains minimal. As such, N‑Acetyl Semax should be regarded as an investigational derivative of Semax with no established, evidence‑based indications in the international literature.

Dosing context

Published dosing information pertains primarily to Semax, most often via intranasal or occasionally parenteral administration in Russian clinical practice. English‑language preclinical studies typically use parenteral dosing in rodents, while clinical practice uses intranasal drops or sprays. Specific human dose ranges for Semax (e.g., µg/kg per day) are described in regional guidelines and product information not indexed in major English databases and therefore are not cited here.

For N‑Acetyl Semax, no controlled pharmacokinetic or dose‑finding studies were identified in PubMed‑indexed sources. Dosing regimens mentioned in non‑indexed materials generally extrapolate directly from Semax intranasal protocols but lack rigorous validation. Consequently, available literature does not support defined, evidence‑based dosing recommendations for N‑Acetyl Semax.

Any dosing or route information for N‑Acetyl Semax should therefore be considered experimental and unsuitable as a basis for clinical prescribing.

Safety profile

Semax

Preclinical and clinical experience with Semax suggests a generally favorable safety profile, with low systemic toxicity and absence of classical ACTH endocrine effects:[11][14][15]

• In rodent stroke models, Semax was not associated with overt behavioral toxicity or worsening of ischemic injury; rather, it improved molecular markers of neuronal survival and plasticity.[11][15]
• In in vitro assays, Semax did not demonstrate intrinsic cytotoxicity at concentrations that prevented Aβ aggregation and protected cell viability.[13][14]

Commonly reported clinical adverse effects in Russian‑language sources (not systematically indexed) include mild local nasal irritation, transient headache, or sleep disturbances, but high‑quality, systematically collected safety datasets are limited in English‑language literature. No strong signals for severe idiosyncratic toxicity, immunogenicity, or endocrine disruption have been reported in the available sources.[11][15]

N‑Acetyl Semax

Direct safety data for N‑Acetyl Semax are not available in the indexed literature. From a structural standpoint, N‑terminal acetylation of small peptides is common and typically reduces immunogenicity and proteolysis, but it can also alter tissue distribution and clearance. Absent dedicated toxicology studies, the following remain uncertain for N‑Acetyl Semax:

• Relative risk of hypersensitivity or immunogenic reactions compared with Semax
• Organ‑specific toxicity or off‑target effects at higher exposures
• Long‑term safety in chronic or repeated use

Given these gaps, N‑Acetyl Semax should be considered insufficiently characterized from a safety standpoint in regulated clinical contexts.

Contraindications and precautions

Formal contraindication lists for Semax or N‑Acetyl Semax are not available in international regulatory documents. Based on mechanistic considerations and extrapolation from Semax:[11][15]

• Caution is reasonable in individuals with a history of peptide allergies or severe atopic disorders.
• Potential interactions with concurrent neuroactive or neuroendocrine medications remain largely unstudied.

High‑quality pharmacovigilance data are lacking outside of national systems.

Regulatory status

• Russian Federation and some CIS countries: Semax is marketed as a neuroprotective and nootropic peptide and is incorporated into local stroke management protocols; detailed agency assessments are not indexed in FDA/EMA databases but are described in regional literature.[11][15]
• United States (FDA): Neither Semax nor N‑Acetyl Semax appears in FDA‑approved drug product databases or guidance documents. There is no evidence of FDA approval for any indication.
• European Union (EMA): Semax and N‑Acetyl Semax are not listed among centrally authorized medicinal products, and no EMA assessment reports were identified.

Accordingly, N‑Acetyl Semax should be regarded as an unapproved, investigational peptide in the US/EU context, with use confined to experimental or unregulated settings and without recognized medicinal product status. Its characterization in the peer‑reviewed literature remains largely indirect, via mechanistic and preclinical data on the parent compound Semax.[11][13][14][15]